ClinicalTrials.gg
CompletedNCT03285321Updated Jan 20, 2026Results posted

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

A Phase 2 interventional study of Nivolumab and Nivolumab in Non-small Cell Lung Cancer, sponsored by Greg Durm, MD. Completed at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-20.

Sponsored by Greg Durm, MD · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
105
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 43 under way, 6 of them phase 3. Nivolumab · Carcinoma, Non-Small-Cell Lung.

Enrollment
39th of 120
105 · median 66
Started
2017
with 23 others
Phase 2
66 of 120
16 open now
Registered
51st of 120
by date

Among the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, this one is the 39th largest by enrollment, is one of 24 that started in 2017, is one of 66 in phase 2, and was the 51st registered.

Carcinoma, Non-Small-Cell Lung

7,632 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,839 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

22 of the 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

17 more — sign in →

By country, each count listing its studies:

All 22 open studies →

About nivolumab

Nivolumab: first FDA approval 2014 (OPDIVO), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 120 studies testing nivolumab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This study is an open label, multicenter, randomized phase II trial of consolidation immunotherapy with either nivolumab alone or the combination of nivolumab and ipilimumab following concurrent chemoradiation in patients with unresectable stage III NSCLC.

Read the detailed description

Patients with unresectable stage IIIA or IIIB NSCLC (unresectable as defined by treating physician) will be treated outside this study with concurrent chemoradiation with one of three chemotherapy regimens (cisplatin/etoposide, cisplatin/pemetrexed, or weekly carboplatin/paclitaxel) in addition to standard dose radiation (dosing can range from 59.4 Gy to 66.6 Gy). If repeat imaging between 28-56 days following completion of chemoradiation shows no progressive or metastatic disease, the patients will be eligible for enrollment on the study.

Randomization and Stratification:

At the time of enrollment, patients will be randomized in a 1:1 fashion to receive either nivolumab 480mg IV every 4 weeks or the combination of nivolumab 3mg/kg IV every 2 weeks with ipilimumab 1mg/kg IV every 6 weeks. Consolidation immunotherapy will be continued until progression or unacceptable toxicity for up to a total of 24 weeks.

Subjects will be stratified by stage (IIIA vs. IIIB) and histology (squamous vs. non-squamous).

Dose Calculations:

Arm 1: The dose of nivolumab will be a fixed dose (not based on subject's weight) at 480mg.

Arm 2: The dose of nivolumab will be weight-based at 3mg/kg. The dose of ipilimumab will be weight-based at 1mg/kg.

Nivolumab Alone (Arm 1):

Arm 1: Nivolumab Administration:

Nivolumab 480 mg will be administered as a 60 minute IV infusion on Day 1 of each 28 day cycle. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -five minutes and +10 minutes is permitted (i.e., infusion time is 60 minutes: -5 min/+10 min). Treatment will continue for up to 6 cycles, in the absence of prohibitive toxicities or disease progression.

Nivolumab Plus Ipilimumab (Arm 2):

Arm 2: Nivolumb Administration:

Nivolumab 3mg/kg will be administered as a 60 minute IV infusion on Day 1, 15, and 29 of each 42 day cycle. Nivolumab should not be given any earlier than 12 days from the previous dose. Sites should make every effort to target infusion timing to be as close to 60 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -five minutes and +10 minutes is permitted (i.e., infusion time is 60 minutes: -5 min/+10 min). Treatment will continue for up to 4 cycles, in the absence of prohibitive toxicities or disease progression.

Arm 2: Ipilimumab Administration:

Ipilimumab 1mg/kg will be administered as a 90 minute IV infusion on Day 1 of each 42 day cycle. Sites should make every effort to target infusion timing to be as close to 90 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -five minutes and +10 minutes is permitted (i.e., infusion time is 60 minutes: -5 min/+10 min). Treatment will continue for up to 4 cycles, in the absence of prohibitive toxicities or disease progression.

On day 1 of cycle 1, nivolumab will be given first, followed by 30 minutes of monitoring, and then ipilimumab given second, followed by 30 minutes of monitoring. If the subject does not have an infusion reaction during the first cycle, the post-ipilimumab monitoring may be discontinued for subsequent cycles at the discretion of the treating physician. Day 1 monitoring between the nivolumab/ipilimumab infusions will continue throughout all 4 cycles. Post nivolumab monitoring on days 15 and 29 is not mandatory and should follow the guidelines of the local infusion center.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Nivolumab
  • Ipilimumab
  • immunotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subject must meet all of the following applicable inclusion criteria to participate in this study:

  • Written and HIPAA authorization for release of personal health information.
  • Age ≥ 18 years at the time of consent.
  • Performance Status of 0 or 1 within 14 days prior to registration.
  • Histological or cytological confirmation of NSCLC. A pathology report confirming the diagnosis of NSCLC must be obtained and reviewed by the treating physician prior to registration to study.
  • Must have unresectable or inoperable stage IIIA or IIIB disease according to the 7th edition IASLC stage classification for lung cancer. Subjects must be considered unresectable or inoperable based on the judgment of the treating physician.
  • Subjects must have completed concurrent chemoradiation with a platinum doublet and a dose of radiation ranging from 59.4-66.6 Gy. Subjects must have stable disease or disease response as evidenced on CT or PET scan evaluation. For those eligible, protocol therapy should begin within 56 days of completing chemoradiation OR Subjects must have completed up to 2 cycles of consolidation therapy started within 56 days of completion of radiation. After completion of consolidation chemotherapy, subjects must have stable disease or disease response as evidenced by CT or PET scan evaluation. For those eligible, protocol therapy should begin within 56 days after the last cycle of chemotherapy.
  • Prior cancer treatment must be completed between 1-56 days prior to registration and the subject must have recovered from all reversible acute toxic effects of the regimen (other than alopecia) to ≤Grade 1 or baseline.
  • Demonstrate adequate organ function, all screening labs to be obtained within 14 days prior to registration:

Hematological:

  • (ANC) ≥ 1.5 K/mm\^3
  • (Hgb) ≥ 9 g/dL
  • ≥100,000/mcl

Renal:

  • Serum creatinine OR Measured or calculated ( can also be used in place of creatinine or CrCl) ≤ 1.5 x (ULN) OR ≥ 60 mL/min for subjects with creatinine levels >1.5 x institutional ULN

Hepatic:

  • ≤ 1.5 × ULN OR Direct bilirubin of ≤ ULN for subjects with total bilirubin levels of >1.5x ULN
  • (AST) ≤ 2.5 × ULN
  • Alanine aminotransferase (ALT) ≤ 2.5 × ULN

Coagulation:

  • (INR) or Prothrombin Time (PT) Activated Partial Thromboplastin Time (aPTT) ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT/INR/PTT is within therapeutic range of intended use of anticoagulants

    • Women of (WOCBP) must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 7 days prior to registration. NOTE: Women are considered of childbearing potential unless they are surgically sterile (have undergone a hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or are . Menopause is defined clinically as 12 months of amenorrhea in a woman over 45 in the absence of other biological or physiological causes. In addition, women under the age of 62 must have a documented serum follicle stimulating hormone (FSH) level less than 40 mIU/mL to be considered post-menopausal.
    • Women of childbearing potential must be willing to abstain from heterosexual activity or use an effective method of from the time of informed consent until 23 weeks after treatment discontinuation.
    • Men who are sexually active with women of childbearing potential (WOCBP) must use any contraceptive method with a failure rate of less than 1% per year. Men receiving study drug and who are sexually active with WOCBP will be instructed to adhere to contraception for a period of 31 weeks after the last dose of product.
    • As determined by the enrolling physician or protocol designee, ability of the subject to understand and comply with study procedures for the entire length of the study.

Exclusion criteria

Exclusion Criteria:

Subjects meeting any of the criteria below may not participate in the study:

  • Pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 23 weeks (female) or 31 weeks (male) after the last dose of trial treatment.
  • Active central nervous system (CNS) . Subjects must undergo a head computed tomography (CT) scan or brain MRI within 28 days prior to registration for protocol therapy to exclude if symptomatic or without prior brain imaging.
  • Treatment with any agent within 28 days prior to registration for protocol therapy.
  • Prior chemotherapy, therapy, or radiotherapy for lung cancer other than standard concurrent chemoradiation or up to 2 cycles of consolidation.
  • Prior therapy with a , PD-L1, PD-L2 or CTLA-4 inhibitor or a lung cancer-specific vaccine therapy.
  • Presence of metastatic disease (stage IV NSCLC) is not allowed. Subjects must be evaluated with a CT or PET scan prior to registration for protocol therapy to exclude metastatic disease.
  • Active second cancers.
  • Evidence of active disease requiring systemic treatment within the past 90 days or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic or agents. Subjects with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Subjects that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Subjects with hypothyroidism stable on hormone replacement or Sjogren's syndrome will not be excluded from the study.
  • Interstitial lung disease or history of pneumonitis requiring treatment with corticosteroids.
  • Diagnosis of immunodeficiency or is receiving chronic systemic corticosteroid therapy or other immunosuppressive therapy (excludes inhaled corticosteroids) within 7 days of first dose of study drug.
  • History of psychiatric illness or social situations that would limit compliance with study requirements.
  • Clinically active infection as judged by the site investigator (≥ Grade 2 by v4).
  • History of (HIV) infection or chronic or C.
  • Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the site investigator.
  • Has a known history of active TB (Bacillus Tuberculosis).
  • to nivolumab, ipilimumab, or any of their .
  • Has received a within 30 days prior to planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however, intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.
Terms in these criteria, in plain language(28)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
105 participants (actual)

Study arms

  • Experimental
    Arm 1

    Nivolumab 480mg IV every 4 weeks for up to 6 cycles

    Drug: Nivolumab

  • Experimental
    Arm 2

    Nivolumab 240mg IV every 2 weeks PLUS Ipilimumab 1mg/kg IV every 6 weeks for up to 4 cycles (12 doses Nivolumab and 4 doses of Ipilimumab)

    Drug: Nivolumab · Drug: Ipilimumab

Interventions

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) at 18-month

    Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. PFS is defined as the time from randomization until the criteria for disease progression is met as defined by RECIST 1.1 or death as a result of any cause.

    Time frame: 18 months

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival is defined as the time from randomization until death from any cause.

    Time frame: 4 years

  2. Time to Metastatic Disease (TTMD) at 36 Month

    TTMD is defined as the time from randomization until evidence of disease outside of the radiated field. The estimate of TTMD at 36 month with 95% confidence interval are reported in the outcome measure data.

    Time frame: 36 Months

  3. Number of Participants With Adverse Events

    Adverse events will be assessed to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.

    Time frame: Up to 12 months

07

Results

Posted Mar 11, 2025

Participant flow

Participant flow — Overall Study
MilestoneArm 1: NivolumabArm 2: Nivolumab Plus Ipilimumab
Started5451
Completed5451
Not completed00

Outcome measures

PrimaryProgression Free Survival (PFS) at 18-month

Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Progressive Disease (PD) \>= 20% increase in tumor burden relative to nadir or the appearance of one or more new lesions; Stable Disease (SD), not meet criteria for CR/PR/PD. PFS is defined as the time from randomization until the criteria for disease progression is met as defined by RECIST 1.1 or death as a result of any cause.

Time frame:
18 months
Reported as:
Number · Percentage of participants
Progression Free Survival (PFS) at 18-month
Percentage of participantsArm 1: NivolumabArm 2: Nivolumab Plus Ipilimumab
Progression Free Survival (PFS) at 18-month65.5 (49.8 to 77.3)66.3 (56.3 to 74.5)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization until death from any cause.

Time frame:
4 years
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm 1: NivolumabArm 2: Nivolumab Plus Ipilimumab
Overall Survival (OS)32 (32 to NA)NA (30.9 to NA)
SecondaryTime to Metastatic Disease (TTMD) at 36 Month

TTMD is defined as the time from randomization until evidence of disease outside of the radiated field. The estimate of TTMD at 36 month with 95% confidence interval are reported in the outcome measure data.

Time frame:
36 Months
Reported as:
Number · Percentage of participants
Time to Metastatic Disease (TTMD) at 36 Month
Percentage of participantsArm 1: NivolumabArm 2: Nivolumab Plus Ipilimumab
Time to Metastatic Disease (TTMD) at 36 Month79.7 (61 to 90.1)77.5 (58.2 to 88.7)
SecondaryNumber of Participants With Adverse Events

Adverse events will be assessed to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.

Time frame:
Up to 12 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsArm 1: NivolumabArm 2: Nivolumab Plus Ipilimumab
Number of Participants With Adverse Events5451

Adverse events

Collected over All-Cause Mortality was monitored up to a maximum of 4 Years. Serious Adverse Events and Other (Not Including Serious) Adverse Events were monitored up to 12 months.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm 1: Nivolumab14/54 (25.9%)10/54 (18.5%)52/54 (96.3%)
Arm 2: Nivolumab Plus Ipilimumab15/51 (29.4%)21/51 (41.2%)51/51 (100%)
Most frequent serious events
Showing 10 of 27
Most frequent serious events
EventArm 1: NivolumabArm 2: Nivolumab Plus Ipilimumab
PNEUMONITISRESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS5/549/51
DYSPNEARESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS1/543/51
LUNG INFECTIONINFECTIONS AND INFESTATIONS3/543/51
THROMBOEMBOLIC EVENTVASCULAR DISORDERS1/542/51
COLITISGASTROINTESTINAL DISORDERS0/542/51
HYPOXIARESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS0/542/51
PLEURAL EFFUSIONRESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS0/542/51
SEPSISINFECTIONS AND INFESTATIONS2/540/51
INFECTIONS AND INFESTATIONS - OTHER, SPECIFYINFECTIONS AND INFESTATIONS1/541/51
BRONCHOPULMONARY HEMORRHAGERESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS0/541/51
Most frequent other events
Showing 10 of 172
Most frequent other events
EventArm 1: NivolumabArm 2: Nivolumab Plus Ipilimumab
FATIGUEGENERAL DISORDERS AND ADMINISTRATION SITE CONDITIONS22/5425/51
COUGHRESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS16/5424/51
DYSPNEARESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS18/5424/51
DIARRHEAGASTROINTESTINAL DISORDERS9/5416/51
HEADACHENERVOUS SYSTEM DISORDERS12/5416/51
NAUSEAGASTROINTESTINAL DISORDERS13/5415/51
PNEUMONITISRESPIRATORY, THORACIC AND MEDIASTINAL DISORDERS10/5415/51
PRURITUSSKIN AND SUBCUTANEOUS TISSUE DISORDERS8/5414/51
ANEMIABLOOD AND LYMPHATIC SYSTEM DISORDERS6/5413/51
RASH MACULO-PAPULARSKIN AND SUBCUTANEOUS TISSUE DISORDERS10/5412/51

Baseline characteristics

Age, Continuous
Age, Continuous(years)Arm 1: NivolumabArm 2: Nivolumab Plus IpilimumabTotal
Median65 (44 to 82)63 (41 to 83)64 (41 to 83)
Sex: Female, Male
Sex: Female, Male(Participants)Arm 1: NivolumabArm 2: Nivolumab Plus IpilimumabTotal
Female302252
Male242953
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm 1: NivolumabArm 2: Nivolumab Plus IpilimumabTotal
American Indian or Alaska Native011
Asian101
Native Hawaiian or Other Pacific Islander000
Black or African American101626
White423072
More than one race011
Unknown or Not Reported134
Region of Enrollment
Region of Enrollment(participants)Arm 1: NivolumabArm 2: Nivolumab Plus IpilimumabTotal
United States5451105
ECOG Performance Status
ECOG Performance Status(Participants)Arm 1: NivolumabArm 2: Nivolumab Plus IpilimumabTotal
ECOG = 0182745
ECOG = 1362460
08

Study locations

12 sites
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
  • University of Illinois Cancer Center
    Chicago, Illinois 60612, United States
  • Indiana University
    Indianapolis, Indiana 46202, United States
  • University of Louisville James Graham Brown Cancer Center
    Louisville, Kentucky 40202, United States
  • Johns Hopkins Sidney Kimmel Comprehensive
    Baltimore, Maryland 21287, United States
  • Karmanos Cancer Center (Wayne State University)
    Detroit, Michigan 48201, United States
  • Michigan State University
    Lansing, Michigan 48910, United States
  • University of Minnesota
    Minneapolis, Minnesota 55455, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08903, United States
  • Penn State Cancer Institute
    Hershey, Pennsylvania 17033, United States
  • University of Wisconsin
    Madison, Wisconsin 53705, United States
09

References and documents

Publications

  • Jun S, Shukla NA, Durm G, Hui AB, Cao S, Ganti AK, Jabbour SK, Kunder C, Alizadeh AA, Hanna NH, Diehn M. Analysis of Circulating Tumor DNA Predicts Outcomes of Short-Course Consolidation Immunotherapy in Unresectable Stage III NSCLC. J Thorac Oncol. 2024 Oct;19(10):1427-1437. doi: 10.1016/j.jtho.2024.06.024. Epub 2024 Jul 5. PubMed 38971369 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Oct 2023, 72 months.

Results were first posted in Mar 2025, 1 year 4 months after primary completion.

Of 729 non-industry phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 84. This study's 72 months is above that.

Counting every sponsor, half of 1,046 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2017
First posted
Sep 18, 2017
StartActual
Sep 15, 2017
Primary completionActual
Oct 13, 2023
CompletionActual
Feb 6, 2024
Results first posted
Mar 11, 2025
Last update
Jan 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03285321
Lead sponsor
Greg Durm, MD
Collaborators
Bristol-Myers Squibb, Big Ten Cancer Research Consortium
Responsible party
Greg Durm, MD (Sponsor-Investigator, Big Ten Cancer Research Consortium) — Sponsor-investigator
First posted
Sep 18, 2017
Start date
Sep 15, 2017
Primary completion
Oct 13, 2023
Completion
Feb 6, 2024
Results posted
Mar 11, 2025
Last update
Jan 20, 2026

Study contacts

Greg Durm, M.D.
study chair · Indiana University Health Simon Cancer Center

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nivolumab · Ipilimumab

Start the discussion